Introduction
The J.P. Morgan Healthcare Conference (JPM), held each January in San Francisco, is the healthcare industry's most important gathering. The 2026 edition ran January 12-15 and drew more than 8,000 attendees, including pharma CEOs, biotech founders, PE investors and bankers, for a week of presentations, meetings and deal discussions. For healthcare investment bankers, JPM sets the strategic agenda for the year. The themes that emerge inform deal pipelines, valuation expectations and the market questions interviewers ask candidates throughout the recruiting cycle.
The Five Themes of JPM 2026
Theme 1: Pragmatic Optimism
The overall mood at JPM 2026 was cautious, pragmatic optimism. A year earlier, the industry arrived braced for an incoming administration threatening pharmaceutical tariffs and most-favored-nation (MFN) drug pricing, and 2024 had not produced a single biopharma acquisition above $5 billion. By January 2026 the worst-case scenarios had not materialized and the fundamentals had improved: the M&A supercycle was producing deal flow, with several 2025 transactions above $10 billion (Johnson & Johnson/Intra-Cellular at $14.6 billion, Novartis/Avidity at roughly $12 billion), and the biotech IPO market was thawing. The shift was from waiting to execution.
- JPM Healthcare Conference
The annual J.P. Morgan Healthcare Conference, held in San Francisco each January, is the healthcare industry's largest and most influential investor conference. Hundreds of public and private companies present, and thousands of side meetings occur across hotels throughout the city. JPM functions as an informal deal market: companies signal strategic intent in their presentations, bankers arrange introductions, and many M&A processes are initiated during the conference week. For healthcare IB candidates, knowing the conference's key themes demonstrates industry engagement and current awareness.
Theme 2: Cardiometabolic Disease as the Central Investment Thesis
The GLP-1 revolution arrived at JPM 2026 as far more than an obesity and diabetes story. Semaglutide and tirzepatide labels already span cardiovascular risk reduction, MASH (liver disease), chronic kidney disease and obstructive sleep apnea, so the conversation moved to the next phase of the market: oral formulations (Novo Nordisk launched the Wegovy pill on January 5, a week before the conference), next-generation multi-agonists, manufacturing capacity and reimbursement. The cardiometabolic thesis argues that metabolic dysfunction, and the chronic inflammation around it, is a root cause of multiple chronic diseases, so assets acting on those pathways (incretin combinations, amylin analogs, FGF21 analogs, anti-inflammatory mechanisms) address a multi-hundred-billion-dollar opportunity across indications. Lilly's $1.2 billion agreement to buy Ventyx Biosciences, announced January 7, fits the pattern: Ventyx's oral NLRP3 inhibitors target the inflammation underneath cardiometabolic disease.
Theme 3: AI Maturation
At JPM 2025, AI in healthcare was a differentiator that companies highlighted prominently. By JPM 2026 it read as expected infrastructure, and the biggest AI headline was a capital commitment rather than a slide: Lilly and NVIDIA announced a co-innovation lab in the San Francisco Bay Area, backed by up to $1 billion over five years in talent, infrastructure and compute. Companies without AI capabilities in drug discovery, clinical trial design or manufacturing are now viewed as behind, so "we use AI" is no longer a compelling pitch point. The question is whether the capability produces measurable outcomes: shorter timelines, higher success rates, lower costs.
Theme 4: M&A Discipline Over Megadeal Frenzy
Dealmakers arrived expecting a megadeal wave, helped by more forgiving antitrust review under the Trump administration, yet the week itself was disciplined rather than frantic. Much of the activity came through licensing agreements and bolt-ons, and the only megadeal signed during the conference was in medtech: Boston Scientific agreed to acquire Penumbra on January 15 at an enterprise value of about $14.5 billion, buying scaled entry into thrombectomy and neurovascular devices. Integration experience reinforces the caution: Amgen's $27.8 billion Horizon acquisition has leaned on a Tepezza franchise whose sales have been uneven. The exception is patent cliff urgency. Merck, facing Keytruda's loss of exclusivity, was linked to a roughly $30 billion bid for Revolution Medicines around the conference, then ended talks over price later in January, a sign that even urgent buyers hold a valuation line.
Theme 5: Policy Absorption
By JPM 2026, the industry had largely absorbed the policy shocks of 2025. The largest was MFN pricing: by December 19, 2025, the White House had announced 14 MFN agreements with major drugmakers, which offered Medicaid MFN prices, MFN-based pricing for new medicines and discounted direct-to-patient sales through TrumpRx in exchange for relief from threatened pharmaceutical tariffs. The BIOSECURE Act became law in December 2025 through the annual defense bill, and the IRA continued to shape portfolios. Companies presented concrete adaptations: direct-to-patient pricing, US manufacturing investments (a tariff and BIOSECURE response) and portfolio shifts toward biologics and orphan drugs (an IRA response). Uncertainty has not vanished, particularly for smaller companies facing MFN negotiations, and antitrust enforcement remains a variable even after easing. The theme was not that policy risk has diminished but that companies now have strategies to operate within the new policy framework.
The next article covers the BIOSECURE Act and China decoupling, examining how supply chain reshoring is reshaping the CRO/CDMO competitive landscape.
